LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 25

Search options

  1. Article: Role of Intestinal Ultrasound in the Management of Patients with Inflammatory Bowel Disease.

    Jauregui-Amezaga, Aranzazu / Rimola, Jordi

    Life (Basel, Switzerland)

    2021  Volume 11, Issue 7

    Abstract: Intestinal ultrasound (IUS) has gained popularity as a first line technique for the diagnosis and monitoring of patients with inflammatory bowel diseases (IBD) due to its many advantages. It is a non-invasive imaging technique with non-ionizing radiation ...

    Abstract Intestinal ultrasound (IUS) has gained popularity as a first line technique for the diagnosis and monitoring of patients with inflammatory bowel diseases (IBD) due to its many advantages. It is a non-invasive imaging technique with non-ionizing radiation exposure. It can be easily performed not only by radiologists but also by trained gastroenterologists at outpatient clinics. In addition, the cost of IUS equipment is low when compared with other imaging techniques. IUS is an accurate technique to detect inflammatory lesions and complications in the bowel in patients with suspected or already known Crohn's disease (CD). Recent evidence indicates that IUS is a convenient and accurate technique to assess extension and activity in the colon in patients with ulcerative colitis (UC), and can be a non-invasive alternative to endoscopy. In patients with IBD, several non-specific pathological ultrasonographic signs can be identified: bowel wall thickening, alteration of the bowel wall echo-pattern, loss of bowel stratification, increased vascularization, decreased bowel peristalsis, fibro-fatty proliferation, enlarged lymph nodes, and/or abdominal free fluid. Considering the transmural CD inflammation, CD complications such as presence of strictures, fistulae, or abscesses can be detected. In patients with UC, where inflammation is limited to mucosa, luminal inflammatory ultrasonographic changes are similar to those of CD. As the technique is related to the operator's experience, adequate IUS training, performance in daily practice, and a generalized use of standardized parameters will help to increase its reproducibility.
    Language English
    Publishing date 2021-06-23
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662250-6
    ISSN 2075-1729
    ISSN 2075-1729
    DOI 10.3390/life11070603
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Role of Intestinal Ultrasound in the Management of Patients with Inflammatory Bowel Disease

    Aranzazu Jauregui-Amezaga / Jordi Rimola

    Life, Vol 11, Iss 603, p

    2021  Volume 603

    Abstract: Intestinal ultrasound (IUS) has gained popularity as a first line technique for the diagnosis and monitoring of patients with inflammatory bowel diseases (IBD) due to its many advantages. It is a non-invasive imaging technique with non-ionizing radiation ...

    Abstract Intestinal ultrasound (IUS) has gained popularity as a first line technique for the diagnosis and monitoring of patients with inflammatory bowel diseases (IBD) due to its many advantages. It is a non-invasive imaging technique with non-ionizing radiation exposure. It can be easily performed not only by radiologists but also by trained gastroenterologists at outpatient clinics. In addition, the cost of IUS equipment is low when compared with other imaging techniques. IUS is an accurate technique to detect inflammatory lesions and complications in the bowel in patients with suspected or already known Crohn’s disease (CD). Recent evidence indicates that IUS is a convenient and accurate technique to assess extension and activity in the colon in patients with ulcerative colitis (UC), and can be a non-invasive alternative to endoscopy. In patients with IBD, several non-specific pathological ultrasonographic signs can be identified: bowel wall thickening, alteration of the bowel wall echo-pattern, loss of bowel stratification, increased vascularization, decreased bowel peristalsis, fibro-fatty proliferation, enlarged lymph nodes, and/or abdominal free fluid. Considering the transmural CD inflammation, CD complications such as presence of strictures, fistulae, or abscesses can be detected. In patients with UC, where inflammation is limited to mucosa, luminal inflammatory ultrasonographic changes are similar to those of CD. As the technique is related to the operator’s experience, adequate IUS training, performance in daily practice, and a generalized use of standardized parameters will help to increase its reproducibility.
    Keywords IUS ; bowel ultrasound ; inflammatory bowel diseases ; IBD ; Crohn’s disease ; ulcerative colitis ; Science ; Q
    Subject code 610
    Language English
    Publishing date 2021-06-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study.

    Holvoet, Tom / Truyens, Marie / De Galan, Cara / Peeters, Harald / Gismero, Francisco Mesonero / Elorza, Ainara / Torres, Paola / Vandermeulen, Liv / Jauregui-Amezaga, Aranzazu / Ferreiro-Iglesias, Rocio / Zabana, Yamile / Reverter, Laia Peries / Geldof, Jeroen / Lobatón, Triana

    Journal of clinical medicine

    2024  Volume 13, Issue 2

    Abstract: Background: Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of the current study was to assess the safety and effectiveness of both in an elderly real-life population.: Methods: A ... ...

    Abstract Background: Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of the current study was to assess the safety and effectiveness of both in an elderly real-life population.
    Methods: A multicentric retrospective study was performed on IBD patients who started vedolizumab or ustekinumab between 2010 and 2020. Clinical and endoscopic remission rates and (serious) adverse events (AE) were assessed.
    Results: A total of 911 IBD patients were included, with 171 (19%) aged above 60 (111 VDZ, 60 UST). Elderly patients treated with vedolizumab or ustekinumab had an increased risk for non-IBD hospitalization (10.5% vs. 5.7%,
    Conclusions: Ustekinumab and vedolizumab show comparable effectiveness and safety in the elderly IBD population. Elderly IBD patients have an increased risk for non-IBD hospitalizations and malignancy compared to the younger IBD population, with corticosteroid use as the main risk factor.
    Language English
    Publishing date 2024-01-09
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm13020365
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: IL-22-Activated

    Breugelmans, Tom / Arras, Wout / Oosterlinck, Baptiste / Jauregui-Amezaga, Aranzazu / Somers, Michaël / Cuypers, Bart / Laukens, Kris / De Man, Joris G / De Schepper, Heiko U / De Winter, Benedicte Y / Smet, Annemieke

    Cells

    2023  Volume 12, Issue 9

    Abstract: Overexpression of the transmembrane mucin MUC13, as seen in inflammatory bowel diseases (IBD), could potentially impact barrier function. This study aimed to explore how inflammation-induced MUC13 disrupts epithelial barrier integrity by affecting ... ...

    Abstract Overexpression of the transmembrane mucin MUC13, as seen in inflammatory bowel diseases (IBD), could potentially impact barrier function. This study aimed to explore how inflammation-induced MUC13 disrupts epithelial barrier integrity by affecting junctional protein expression in IBD, thereby also considering the involvement of MUC1. RNA sequencing and permeability assays were performed using LS513 cells transfected with
    MeSH term(s) Animals ; Mice ; Colitis/chemically induced ; Colitis/metabolism ; Inflammation/metabolism ; Inflammatory Bowel Diseases/metabolism ; Intestinal Mucosa/metabolism ; Mucins/metabolism ; rho-Associated Kinases/metabolism ; Interleukin-22
    Chemical Substances Mucins ; rho-Associated Kinases (EC 2.7.11.1) ; Rock2 protein, mouse (EC 2.7.11.1) ; Ly64 protein, mouse
    Language English
    Publishing date 2023-04-23
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2661518-6
    ISSN 2073-4409 ; 2073-4409
    ISSN (online) 2073-4409
    ISSN 2073-4409
    DOI 10.3390/cells12091224
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus.

    Desmedt, Valérie / Jauregui-Amezaga, Aranzazu / Fierens, Liselotte / Aspeslagh, Sandrine / Dekervel, Jeroen / Wauters, Els / Peeters, Marc / Sabino, Joao / Crapé, Lara / Somers, Michael / Hoorens, Anne / Dutré, Joris / Lobatón, Triana

    European journal of cancer (Oxford, England : 1990)

    2023  Volume 187, Page(s) 36–57

    Abstract: Introduction: The use of immune checkpoint inhibitors (ICIs) in cancer immunotherapy has shown increased overall survival in a wide range of cancer types with the associated risk of developing severe immune-mediated adverse events, commonly involving ... ...

    Abstract Introduction: The use of immune checkpoint inhibitors (ICIs) in cancer immunotherapy has shown increased overall survival in a wide range of cancer types with the associated risk of developing severe immune-mediated adverse events, commonly involving the gastrointestinal tract.
    Aim: The aim of this position statement is to provide an updated practice advice to the gastroenterologists and oncologists on the diagnosis and management of ICI-induced gastrointestinal toxicity.
    Methodology: The evidence reviewed in this paper includes a comprehensive search strategy of English language publications. Consensus was reached using a three-round modified Delphi methodology and approved by the members of the Belgian Inflammatory Bowel Disease Research and Development Group (BIRD), Belgian Society of Medical Oncology (BSMO), Belgian group of Digestive Oncology (BGDO), and Belgian Respiratory Society (BeRS).
    Conclusions: The management of ICI-induced colitis requires an early multidisciplinary approach. A broad initial assessment is necessary (clinical presentation, laboratory markers, endoscopic and histologic examination) to confirm the diagnosis. Criteria for hospitalisation, management of ICIs, and initial endoscopic assessment are proposed. Even if corticosteroids are still considered the first-line therapy, biologics are recommended as an escalation therapy and as early treatment in patients with high-risk endoscopic findings.
    MeSH term(s) Humans ; Colitis/chemically induced ; Colitis/diagnosis ; Colitis/therapy ; Consensus ; Delphi Technique ; Immune Checkpoint Inhibitors/adverse effects ; Neoplasms/drug therapy
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2023-03-25
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2023.03.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer.

    Jauregui-Amezaga, Aranzazu / Vermeire, Séverine / Prenen, Hans

    Annals of gastroenterology

    2016  Volume 29, Issue 2, Page(s) 127–136

    Abstract: Patients with inflammatory bowel disease have an additional risk of developing cancer compared with the general population. This is due to local chronic inflammation that leads to the development of gastrointestinal cancers and the use of thiopurines, ... ...

    Abstract Patients with inflammatory bowel disease have an additional risk of developing cancer compared with the general population. This is due to local chronic inflammation that leads to the development of gastrointestinal cancers and the use of thiopurines, associated with a higher risk of lymphoproliferative disorders, skin cancers, or uterine cervical cancers. Similar to the general population, a previous history of cancer in inflammatory bowel disease patients increases the risk of developing a secondary cancer. Large studies have not shown an increased risk of cancer in patients treated with biologics. In this review we discuss the prevention and treatment of cancer in patients with inflammatory bowel disease.
    Language English
    Publishing date 2016-02-01
    Publishing country Greece
    Document type Journal Article ; Review
    ZDB-ID 2032850-3
    ISSN 1108-7471
    ISSN 1108-7471
    DOI 10.20524/aog.2016.0004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Contemporary methods for the diagnosis and treatment of microscopic colitis.

    Jauregui-Amezaga, Aranzazu / Vermeire, Séverine / Geboes, Karel

    Expert review of gastroenterology & hepatology

    2016  Volume 10, Issue 1, Page(s) 47–61

    Abstract: Microscopic colitis is a common cause of chronic diarrhea. It is characterized by non-bloody watery diarrhea with macroscopically normal colonic mucosa. Its specific histological characteristics confirm the diagnosis. Two distinct histological forms can ... ...

    Abstract Microscopic colitis is a common cause of chronic diarrhea. It is characterized by non-bloody watery diarrhea with macroscopically normal colonic mucosa. Its specific histological characteristics confirm the diagnosis. Two distinct histological forms can be identified, namely, collagenous colitis and lymphocytic colitis. In collagenous colitis, a thick colonic subepithelial collagenous deposit can be observed, whereas in lymphocytic colitis, a pronounced intraepithelial lymphocytic inflammation in the absence of a thickened collagen band can be identified. Microscopic colitis occurs more frequently in elderly females and its etiology is believed to be multifactorial, although smoking and consumption of several drugs have been identified as risks factors for the development of the disease. The treatment is based on avoiding the risks factors and administration of oral budesonide.
    MeSH term(s) Anti-Inflammatory Agents/therapeutic use ; Antidiarrheals/therapeutic use ; Bismuth/therapeutic use ; Budesonide/therapeutic use ; Colitis, Microscopic/diagnosis ; Colitis, Microscopic/drug therapy ; Colitis, Microscopic/epidemiology ; Humans ; Immunosuppressive Agents/therapeutic use ; Induction Chemotherapy ; Maintenance Chemotherapy ; Mesalamine/therapeutic use ; Organometallic Compounds/therapeutic use ; Probiotics/therapeutic use ; Risk Factors ; Salicylates/therapeutic use ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    Chemical Substances Anti-Inflammatory Agents ; Antidiarrheals ; Immunosuppressive Agents ; Organometallic Compounds ; Salicylates ; Tumor Necrosis Factor-alpha ; Mesalamine (4Q81I59GXC) ; Budesonide (51333-22-3) ; bismuth subsalicylate (62TEY51RR1) ; Bismuth (U015TT5I8H)
    Language English
    Publishing date 2016
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2481021-6
    ISSN 1747-4132 ; 1747-4124
    ISSN (online) 1747-4132
    ISSN 1747-4124
    DOI 10.1586/17474124.2016.1096197
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis.

    Jáuregui-Amézaga, Aránzazu / Ricart, Elena / Panés, Julián

    Current drug targets

    2011  Volume 12, Issue 10, Page(s) 1467–1477

    Abstract: The perception that Crohn's disease is a more severe process than ulcerative colitis, led to the initial development of a majority drugs, and testing of treatment strategies, in the former. In the absence of similar studies in ulcerative colitis, ... ...

    Abstract The perception that Crohn's disease is a more severe process than ulcerative colitis, led to the initial development of a majority drugs, and testing of treatment strategies, in the former. In the absence of similar studies in ulcerative colitis, information of Crohn's disease studies may help the clinician in decision making in UC. Studies on aminosalicylates show that drugs with a topical effect which are not effective in Crohn's disease may still have efficacy in ulcerative colitis, and this should be considered in future drug development. The best efficacy of corticorteroids is achieved with high doses of 1 mg/kg/day, and reaching remission may be delayed by several weeks, although non-response in the initial days should lead to treatment escalation, in particular in severe patients. Thiopurines have a steroid-sparing effect, and the duration of treatment should be at least 4 years; caution should be exerted in using these drugs in EBV negative young patients and in the older population for the risk of lymphoma. Anti-TNF monoclonal antibody therapy is optimized by use of induction followed by scheduled maintenance as opposed to episodic treatment, resulting in higher sustained response rates and lower immunogenicity. Associations of non-biological immunosuppressants with anti-TNF antibodies can further increase therapeutic efficacy maintaining a safe profile. Patients under combined therapy with sustained clinical and biological remission and mucosal healing may be candidates to stop anti-TNF treatment. The majority of these recommendations need to be specifically studied in patients with ulcerative colitis before generalization in clinical practice.
    MeSH term(s) Clinical Trials as Topic ; Colitis, Ulcerative/drug therapy ; Colitis, Ulcerative/therapy ; Crohn Disease/drug therapy ; Crohn Disease/therapy ; Humans ; Randomized Controlled Trials as Topic
    Language English
    Publishing date 2011-03-28
    Publishing country United Arab Emirates
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2064859-5
    ISSN 1873-5592 ; 1389-4501
    ISSN (online) 1873-5592
    ISSN 1389-4501
    DOI 10.2174/138945011796818162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab.

    Jauregui-Amezaga, Aranzazu / Somers, Michael / De Schepper, Heiko / Macken, Elisabeth

    Clinical and experimental gastroenterology

    2017  Volume 10, Page(s) 293–301

    Abstract: The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn's disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal ...

    Abstract The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn's disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal antibody which targets the common p40 subunit of the cytokines interleukin-12 as well as interleukin-23. Consequently, the Th1 and Th17 inflammatory responses are inhibited. Ustekinumab has been recently approved for its use in patients with Crohn's disease. Its efficacy and safety was initially proved in patients with psoriasis and psoriatic arthritis. More recently, three Phase III trials have confirmed its efficacy in patients with Crohn's disease refractory to anti-tumor necrosis factor therapy. This biologic agent appears safe, with no increased risk of infectious or malignant complications, and a low immunogenic profile.
    Language English
    Publishing date 2017-11-15
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2520690-4
    ISSN 1178-7023
    ISSN 1178-7023
    DOI 10.2147/CEG.S110546
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: In-Depth Study of Transmembrane Mucins in Association with Intestinal Barrier Dysfunction During the Course of T Cell Transfer and DSS-Induced Colitis.

    Breugelmans, Tom / Van Spaendonk, Hanne / De Man, Joris G / De Schepper, Heiko U / Jauregui-Amezaga, Aranzazu / Macken, Elisabeth / Lindén, Sara K / Pintelon, Isabel / Timmermans, Jean-Pierre / De Winter, Benedicte Y / Smet, Annemieke

    Journal of Crohn's & colitis

    2020  Volume 14, Issue 7, Page(s) 974–994

    Abstract: Background and aims: There is evidence for a disturbed intestinal barrier function in inflammatory bowel diseases [IBD] but the underlying mechanisms are unclear. Because mucins represent the major components of the mucus barrier and disturbed mucin ... ...

    Abstract Background and aims: There is evidence for a disturbed intestinal barrier function in inflammatory bowel diseases [IBD] but the underlying mechanisms are unclear. Because mucins represent the major components of the mucus barrier and disturbed mucin expression is reported in the colon of IBD patients, we studied the association between mucin expression, inflammation and intestinal permeability in experimental colitis.
    Methods: We quantified 4-kDa FITC-dextran intestinal permeability and the expression of cytokines, mucins, junctional and polarity proteins at dedicated time points in the adoptive T cell transfer and dextran sodium sulfate [DSS]-induced colitis models. Mucin expression was also validated in biopsies from IBD patients.
    Results: In both animal models, the course of colitis was associated with increased interleukin-1β [IL-1β] and tumour necrosis factor-α [TNF-α] expression and increased Muc1 and Muc13 expression. In the T cell transfer model, a gradually increasing Muc1 expression coincided with gradually increasing 4-kDa FITC-dextran intestinal permeability and correlated with enhanced IL-1β expression. In the DSS model, Muc13 expression coincided with rapidly increased 4-kDa FITC-dextran intestinal permeability and correlated with TNF-α and Muc1 overexpression. Moreover, a significant association was observed between Muc1, Cldn1, Ocln, Par3 and aPKCζ expression in the T cell transfer model and between Muc13, Cldn1, Jam2, Tjp2, aPkcζ, Crb3 and Scrib expression in the DSS model. Additionally, MUC1 and MUC13 expression was upregulated in inflamed mucosa of IBD patients.
    Conclusions: Aberrantly expressed MUC1 and MUC13 might be involved in intestinal barrier dysfunction upon inflammation by affecting junctional and cell polarity proteins, indicating their potential as therapeutic targets in IBD.
    MeSH term(s) Actins/metabolism ; Animals ; CD4-Positive T-Lymphocytes/transplantation ; Cell Adhesion Molecules/genetics ; Colitis/chemically induced ; Colitis/immunology ; Colitis/physiopathology ; Colitis, Ulcerative/genetics ; Colitis, Ulcerative/metabolism ; Colitis, Ulcerative/physiopathology ; Crohn Disease/genetics ; Crohn Disease/metabolism ; Crohn Disease/physiopathology ; Cytokines/metabolism ; Dextran Sulfate ; Dextrans/pharmacokinetics ; Disease Models, Animal ; Female ; Fluorescein-5-isothiocyanate/analogs & derivatives ; Fluorescein-5-isothiocyanate/pharmacokinetics ; Humans ; Interleukin-10/metabolism ; Interleukin-1beta/metabolism ; Interleukin-6/metabolism ; Intestinal Mucosa/physiopathology ; Male ; Mice, Inbred BALB C ; Mice, SCID ; Mucins/genetics ; Mucins/metabolism ; Myosin-Light-Chain Kinase/genetics ; Permeability ; Peroxidase/metabolism ; Tight Junction Proteins/genetics ; Tumor Necrosis Factor-alpha/metabolism
    Chemical Substances Actins ; Cell Adhesion Molecules ; Cytokines ; Dextrans ; IL10 protein, mouse ; IL1B protein, mouse ; Interleukin-1beta ; Interleukin-6 ; MYLK protein, mouse ; Mucins ; Tight Junction Proteins ; Tumor Necrosis Factor-alpha ; fluorescein isothiocyanate dextran ; interleukin-6, mouse ; Interleukin-10 (130068-27-8) ; Dextran Sulfate (9042-14-2) ; Peroxidase (EC 1.11.1.7) ; Myosin-Light-Chain Kinase (EC 2.7.11.18) ; Fluorescein-5-isothiocyanate (I223NX31W9)
    Language English
    Publishing date 2020-01-30
    Publishing country England
    Document type Journal Article
    ZDB-ID 2390120-2
    ISSN 1876-4479 ; 1873-9946
    ISSN (online) 1876-4479
    ISSN 1873-9946
    DOI 10.1093/ecco-jcc/jjaa015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top